Development of virus-accelerated XXXX in AKR @entity19 .

@entity778 @entity706 @entity19 @entity6732 @entity10235 @entity236
The progression of prelymphoma cells (PLC) in the bone marrow to @entity706 cells (LC) in the thymus in the presence of the lymphomagenic retrovirus SL3-3c was studied in a model system of virus-accelerated @entity6732 in AKR/J @entity19 . On the average, a single LC appears in the thymus 30 days after the neonatal ip inoculation of SL3-3 @entity10235 ; 50 days later, @entity6732 is clinically detectable. PLC in the bone @entity236 in the thymus are continuously present during this period before @entity706 develops. @entity778 in the thymus increases as the animal nears the time of @entity706 development. Intrathymic inoculation, but not ip inoculation, of SL3-3 @entity10235 results in accelerated @entity6732 in 4- to 6-week-old AKR @entity19 . PLC defined as a population of bone marrow-derived thymocyte progenitor cells susceptible to malignant transformation by oncogenic retrovirus after homing to thymus were further studied and characterized. PLC, like normal bone marrow thymocyte progenitors, were found to be radiosensitive and glucocorticoid resistant. Thymocytes of 21- to 28-day-old AKR @entity19 , neonatally inoculated with SL3-3 @entity10235 , were studied for PLC. They could not be detected. It is concluded that @entity706 development is the final outcome of a series of events in which bone marrow-derived thymocyte progenitors are transformed after entering the thymus by virus in the thymic environment.
